These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25791993)

  • 21. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
    Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
    Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy.
    Odano I; Varrone A; Savic I; Ciumas C; Karlsson P; Jucaite A; Halldin C; Farde L
    Neuroimage; 2012 Feb; 59(4):3582-93. PubMed ID: 22056530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
    Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1220-30. PubMed ID: 12811422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simplified quantification of [
    Brumberg J; Kerstens V; Cselényi Z; Svenningsson P; Sundgren M; Fazio P; Varrone A
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1291-1300. PubMed ID: 32955955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
    Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [
    Honhar P; Ebrahimian Sadabad F; Tinaz S; Gallezot JD; Dias M; Naganawa M; Yang Y; Henry S; Hillmer AT; Gao H; Najafzadeh S; Comley R; Nabulsi N; Huang Y; Finnema SJ; Carson RE; Matuskey D
    Brain Commun; 2024; 6(5):fcae345. PubMed ID: 39429243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET imaging of [
    Varnäs K; Cselényi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):367-375. PubMed ID: 30270409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with ¹⁸F-FE-PE2I.
    Ikoma Y; Sasaki T; Kimura Y; Seki C; Okubo Y; Suhara T; Ito H
    Ann Nucl Med; 2015 Oct; 29(8):697-708. PubMed ID: 26134215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
    Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
    J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
    Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
    Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M
    Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.
    Emond P; Guilloteau D; Chalon S
    CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
    Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.
    Leroy C; Karila L; Martinot JL; Lukasiewicz M; Duchesnay E; Comtat C; Dollé F; Benyamina A; Artiges E; Ribeiro MJ; Reynaud M; Trichard C
    Addict Biol; 2012 Nov; 17(6):981-90. PubMed ID: 21812871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study.
    Ma Y; Dhawan V; Mentis M; Chaly T; Spetsieris PG; Eidelberg D
    Synapse; 2002 Aug; 45(2):125-33. PubMed ID: 12112405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers.
    Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A
    Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.